Generally not, because standard drug tests look for THC and its metabolite rather than CBG. The risk sits in the product. Full-spectrum CBG can carry trace THC (up to 0.3%), and that THC can build up with regular use. Data on whether CBG cross-reacts with test assays are limited, so caution is sensible.
No. CBG (cannabigerol) is a separate, non-intoxicating molecule, C₂₁H₃₂O₂. The product around it is another story: full-spectrum hemp products carry trace THC (≤0.3%), while broad-spectrum and isolate products are formulated to remove it. The certificate of analysis tells you which one you have.
Not on its own, since standard tests detect THC rather than CBG. Full-spectrum CBG products, though, carry trace THC that can accumulate with regular use and produce a positive result; isolate and broad-spectrum products carry less of that risk. Cross-reactivity data specific to CBG are limited, graded Low, and no product can be guaranteed test-safe.
CBG is prohibited by the World Anti-Doping Agency — CBD is the only exempt cannabinoid. In a randomised trial of a broad-spectrum CBD product containing only trace CBG, CBG was detectable in urine after repeated daily use, and concentrations appeared higher after exercise. This is regulatory and testing status, not a health claim. Check the current WADA Prohibited List and your product's COA. (Gillham et al., PMID 40920736.)
Cited as an attributed regulatory and testing note. This paper is in intake review and is not yet a graded entry in the CBG Atlas registry, so it carries no evidence grade here.
The same answers on the CBG monograph, in the drug testing group of its common questions. CBG by condition holds the graded claim for each condition people ask about.
CBG acts on α2-adrenoceptors, which help regulate blood pressure; anyone taking cardiovascular medication should consult a clinician before using CBG products. Nothing on this page is medical advice, and no statement here is a claim that CBG treats, cures, or prevents any condition. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.